invitrogen™

ViraPower™ HiPerform™ Lentiviral Expression Systems

Lentiviral systems for high-level expression in dividing and non-dividing mammalian cells

Catalog nos. K5310-00, K5320-00, K5330-00, K5340-00

Version A
13 November, 2007
A10290

User Manual

Table of Contents

Kit Contents and Storage v
Accessory Products viii

Introduction 1

Overview 1
Biosafety Features of the System 5
Biosafety Features of the System, Continued 6
Experimental Outline 7

Methods 8

General Information 8
Generating Your pLenti Expression Construct 9
Producing Lentivirus in 293FT Cells 10
Titering Your Lentiviral Stock 16
Titering Your Lentiviral Stock Using EmGFP 18
Titering Your Lentiviral Stock Using Blasticidin 22
Transduction and Analysis 26
Troubleshooting 30

Appendix 33

Blasticidin 33
Map and Features of pLP1 34
Map and Features of pLP2 36
Map and Features of pLP/VSVG 38
Technical Support 40
Purchaser Notification 41
Gateway® Clone Distribution Policy 47
References 48

Kit Contents and Storage

Types of Kits

This manual is supplied with the kits listed below. The ViraPower™ HiPerform™ Lentiviral Expression Kits include the ViraPower™ HiPerform™ Lentiviral Support Kit, an expression vector, and the 293FT producer cell line. The ViraPower™ Lentiviral Support Kits include the ViraPower™ Packaging Mix, Lipofectamine™ 2000, and a selection agent.

Product	Catalog no.
ViraPower™ HiPerform™ Lentiviral TOPO® Expression Kit	K5310-00
ViraPower™ HiPerform™ Lentiviral FastTiter™ TOPO® Expression Kit	K5320-00
ViraPower™ HiPerform™ Lentiviral Gateway® Expression Kit	K5330-00
ViraPower™ HiPerform™ Lentiviral FastTiter™ Gateway® Expression Kit	K5340-00

System Components

The following table shows the components associated with ViraPower™ HiPerform™ Lentiviral Expression Kits listed above.

Components	Catalog no.			
	K5310-00	K5320-00	K5330-00	K5340-00
pLenti6.3/V5-TOPO® TA Cloning Kit	✓			
pLenti7.3/V5-TOPO® TA Cloning Kit		✓		
pLenti6.3/V5-DEST Gateway® Vector Kit			✓	
pLenti7.3/V5-DEST Gateway® Vector Kit				✓
ViraPower™ Lentiviral Support Kit	✓	✓	✓	✓
One Shot® Stbl3™ Chemically Competent *E. coli*	✓	✓	✓	✓
293FT Cell Line	✓	✓	✓	✓
Blasticidin	✓		✓	

Continued on next page

Kit Contents and Storage, Continued

Shipping/Storage

The ViraPower™ HiPerform™ Lentiviral products are shipped as described below. Upon receipt, store each component as detailed below.

Item	Shipping	Storage
293FT Cell Line	Dry ice	Liquid nitrogen
Blasticidin	Room temperature	-20°C
ViraPower™ Packaging Mix	Room temperature	-20°C
ViraPower™ Lentiviral Support Kit: • ViraPower™ Packaging Mix • Lipofectamine™ 2000	Blue ice	 -20°C +4°C **(do not freeze)**
pLenti6.3/V5-TOPO® TA Cloning Kit: • Vectors • One Shot® Stbl3™ Chemically Competent *E. coli*	Dry ice	 -20°C -80°C
pLenti7.3/V5-TOPO® TA Cloning Kit: • Vectors • One Shot® Stbl3™ Chemically Competent *E. coli*	Dry ice	 -20°C -80°C
pLenti6.3/V5-DEST Gateway® Vector Kit: • Vectors • One Shot® Stbl3™ Chemically Competent *E. coli*	Dry ice	 -20°C -80°C
pLenti7.3/V5-DEST Gateway® Vector Kit: • Vectors • One Shot® Stbl3™ Chemically Competent *E. coli*	Dry ice	 -20°C -80°C

Expression Vectors

Each ViraPower™ HiPerform™ Lentiviral Expression Kit also includes a pLenti-based expression vector kit. The expression vector kit includes:

- A pLenti-based expression vector for cloning your gene of interest
- A corresponding expression control plasmid
- One Shot® Stbl3™ Chemically Competent *E. coli* for transformation

Expression vectors offered in the kits include pLenti6.3/V5-TOPO® vector (Catalog no. K5310-00), pLenti7.3/V5-TOPO® vector (Catalog no. K5320-00), pLenti6.3/V5-DEST Gateway vector (Catalog no. K5330-00), and pLenti7.3/V5-DEST Gateway vector (Catalog no. K5340-00). Refer to the appropriate vector manual supplied with the kit for a detailed description of the reagents provided with each vector kit and instructions to generate an expression clone containing your gene of interest.

Continued on next page

ViraPower™ Lentiviral Support Kit Contents

The ViraPower™ HiPerform™ Lentiviral Support Kit includes the following vectors and reagents. Store as directed below.

Important: Store Lipofectamine™ 2000 at +4°C. **DO NOT FREEZE.**

Reagent	Composition	Quantity	Storage
ViraPower™ Packaging Mix	Contains a mixture of the pLP1, pLP2, and pLP/VSVG plasmids, lyophilized in TE, pH 8.0	195 µg	-20°C
Lipofectamine™ 2000	Proprietary	0.75 ml	+4°C

ViraPower™ Packaging Mix

The ViraPower™ Packaging Mix contains 3 tubes with 195 µg DNA per tube. Upon receipt, store at -20°C.

One Shot® Stbl3™ Chemically Competent *E. coli*

The following reagents are included with the One Shot® Stbl3™ Chemically Competent *E. coli* kit. Transformation efficiency is ≥ 1 x 10^8 cfu/µg plasmid DNA. **Store at -80°C.**

Reagent	Composition	Qunatity
S.O.C. Medium	2% Tryptone 0.5% Yeast Extract 10 mM NaCl 2.5 mM KCl 10 mM $MgCl_2$ 10 mM $MgSO_4$ 20 mM glucose	6 ml
Stbl3™ Cells	--	21 x 50 µl
pUC19 Control DNA	10 pg/µl in 5 mM Tris-HCl, 0.5 mM EDTA, pH 8	50 µl

Genotype of Stbl3™ Cells

F$^-$ *mcr*B *mrr hsd*S20(r_B^-, m_B^-) *rec*A13 *sup*E44 *ara*-14 *gal*K2 *lac*Y1 *pro*A2 *rps*L20(Str^R) *xyl*-5 λ$^-$ *leu mtl*-1

Note: This strain is *end*A1+

293FT Cell Line

Each ViraPower™ HiPerform™ Lentiviral Expression Kit includes the 293FT producer cell line. The 293FT Cell Line is supplied as one vial containing 3 x 10^6 frozen cells in 1 ml of Freezing Medium. **Upon receipt, store in liquid nitrogen.**

For instructions to thaw, culture, and maintain the 293FT Cell Line, see the 293FT Cell Line manual, included with the ViraPower™ HiPerform™ Lentiviral Expression Kit. To download the manual, visit our website at www.invitrogen.com, or contact **Technical Support** (page 40).

Accessory Products

Introduction

The products listed in this section may be used with the ViraPower™ HiPerform™ Lentiviral Expression Kits. For more information, visit www.invitrogen.com or contact **Technical Support** (see page 40).

Additional Products

Many of the reagents supplied in the ViraPower™ HiPerform™ Lentiviral Expression Kits as well as other products suitable for use with the kits are available separately from Invitrogen. Ordering information for these reagents is provided below.

Item	Quantity	Catalog no.
pLenti6.3/V5 TOPO® TA Cloning Kit	20 reactions	K5315-20
pLenti7.3/V5-TOPO® TA Cloning Kit	20 reactions	K5325-20
pLenti6.3/V5-DEST Gateway® Vector Kit	6 µg	V533-06
pLenti7.3/V5-DEST Gateway® Vector Kit	6 µg	V534-06
Vivid Colors™ pLenti6.3/V5-GW/EmGFP Expression Control Vector	20 µg	V370-06
PureLink™ HiPure Plasmid Midiprep Kit	25 reactions	K2100-04
	50 reactions	K2100-05
One Shot® Stbl3™ Chemically Competent *E. coli*	20 x 50 µl	C7373-03
293FT Cell Line	3 x 10^6 cells, frozen	R700-07
Lipofectamine™ 2000	0.75 ml	11668-027
	1.5 ml	11668-019
Opti-MEM® I Reduced Serum Medium	100 ml	31985-062
	500 ml	31985-070
Dulbecco's Modified Eagle Medium (D-MEM)	500 ml	11965-092
	1000 ml	11965-084
TrypLE™ Select (1X), liquid	500 ml	12563-029
TrypLE™ Select Animal-Origin-Free Trypsin-Like Enzyme	100 ml	12563-011
Propidium Iodide	100 mg	P-3566
Blasticidin	50 mg	R210-01
Geneticin®	20 ml	10131-035
	100 ml	10131-027
Fetal Bovine Serum (FBS), Certified	500 ml	16000-044
Phosphate-Buffered Saline (PBS), pH 7.4	500 ml	10010-023
	1 L	10010-031

Introduction

Overview

Introduction

The new ViraPower™ HiPerform™ Lentiviral Expression Systems allow the creation of a replication-incompetent, HIV-1-based lentivirus that is used to deliver and express your gene of interest in either dividing or non-dividing mammalian cells. The new expressions Systems use four new expression vectors: two pLenti Gateway Destination vectors that are adapted for use with the Gateway® technology (pLenti6.3/V5-DEST Gateway® vector and pLenti7.3/V5-DEST Gateway vector) and two pLenti TOPO® vectors that combine the ViraPower™ HiPerform™ Lentiviral Expression Systems with the rapid TOPO® Cloning technology (pLenti6.3/V5-TOPO® vector, and pLenti7.3/V5-TOPO® vector). For more information on these new vectors, refer to the section below.

ViraPower™ HiPerform™ Lentiviral Expression Vectors

The new ViraPower™ HiPerform™ Lentiviral Expression vectors contain two new elements (WPRE and cPPT) to yield cell-specific, high performance results. The **WPRE** (Woodchuck Posttranscriptional Regulatory Element) from the woodchuck hepatitis virus, is placed directly downstream of the gene of interest, allowing for increased transgene expression(Zufferey *et al.*, 1998), with more cells expressing your gene of interest. **cPPT** (Polypurine Tract) from the HIV-1 integrase gene, increases the copy number of lentivirus integrating into the host genome (Park, 2001) and allows for a two-fold increase in viral titer. Both WPRE and cPPT together, produce at least a four-fold increase in protein expression in most cell types, compared to other vectors that do not contain these elements. The ViraPower™ HiPerform™ Lentiviral **FastTiter**™ Expression Systems (Catalog nos. K5320-00 and K5340-00) allow for an accurate titer of functional lenti virus in just **two days** using EmGFP.

The ViraPower™ HiPerform™ Lentiviral Expression System vectors also contain:

- Human cytomegalovirus (CMV) immediate early promoter to control high-level expression of the gene of interest in all four vectors.
- C-terminal V5 tag for convenient detection.
- SV40 promoter driving expression of Blasticidin (pLenti6.3/V5-DEST Gateway® vector and pLenti6.3/V5-TOPO® Vector), **or** EmGFP (pLenti7.3/V5-DEST Gateway® vector and pLenti7.3/V5-TOPO® vector).
- Blasticidin (Izumi *et al.*, 1991; Kimura *et al.*, 1994; Takeuchi *et al.*, 1958; Yamaguchi *et al.*, 1965) resistance gene for stable transduction and selection in *E. coli* and mammalian cells (pLenti6.3/V5-DEST Gateway® and pLenti6.3/V5-TOPO® TA vectors, only) **or**
- Emerald Green Fluorescent Protein (EmGFP, derived from *Aequorea Victoria* GFP, pLenti7.3/V5-DEST Gateway® and pLenti7.3/V5-TOPO® vectors only) which allows you to easily determine the Lentiviral titer by flow cytometry.

Continued on next page

Components of the ViraPower™ HiPerform™ Lentiviral Expression System

The ViraPower™ HiPerform™ Lentiviral Expression Systems facilitate highly efficient, *in vitro* delivery of a target gene to dividing and non-dividing mammalian cells using a replication-incompetent lentivirus. Based on the lentikat™ system developed by Cell Genesys (Dull *et al.*, 1998), the ViraPower™ HiPerform™ Lentiviral Expression System possesses features which enhance its biosafety while allowing high-level gene expression in a wider range of cell types than traditional retroviral systems. The System includes the following major components:

- A pLenti-based expression vector into which the gene of interest will be cloned. The vector contains the WPRE and cPPT elements for higher levels of gene expression, with more cells expressing your gene of interest, and faster titering times. The vector also contains the elements required to allow packaging of the expression construct into virions (*e.g.*, 5′ and 3′ LTRs, Ψ packaging signal). For more information about the pLenti expression vectors, refer to the manual for the specific vector you are using.
- The ViraPower™ Packaging Mix that contains an optimized mixture of the three packaging plasmids, pLP1, pLP2, and pLP/VSVG. These plasmids supply the helper functions as well as structural and replication proteins *in trans* required to produce the lentivirus. For more information about the packaging plasmids, see the **Appendix**, pages 34-39.
- VSV Envelope Glycoprotein: Most retroviral vectors are limited in their usefulness as gene delivery vehicles by their restricted tropism and generally low titers. In the ViraPower™ HiPerform™ Lentiviral Expression System, this limitation has been overcome by use of the G glycoprotein gene from Vesicular Stomatitis Virus (VSV-G) as a pseudotyping envelope, thus allowing production of a high titer lentiviral vector with a significantly broadened host cell range (Burns *et al.*, 1993; Emi *et al.*, 1991; Yee *et al.*, 1994).
- An optimized 293FT producer cell line that stably expresses the SV40 large T antigen under the control of the human CMV promoter and facilitates optimal production of virus. For more information about the 293FT Cell Line, refer to the 293FT Cell Line manual.

You will cotransfect the ViraPower™ Packaging Mix and the pLenti vector containing your gene of interest into 293FT cells to produce a replication-incompetent lentivirus, which is used to transduce a mammalian cell line of interest.

Continued on next page

Features of the ViraPower™ HiPerform™ Lentiviral Systems

The major Features of the ViraPower™ HiPerform™ Lentiviral Systems include:

- An expression plasmid containing the gene of interest under the control a CMV early promoter, and elements that allow packaging of the construct into virions.
- Polypurine Tract from HIV (cPPT) for increased viral titer (Park et al., 2001).
- Woodchuck Posttranscriptional Regulatory Element (WPRE) for increased transgene expression (Zufferey et al., 1999).
- An optimized mix of the three packaging plasmids (pLP1, pLP2, and pLP/VSVG) that supply the structural and replication proteins *in trans* that are required to produce the lentivirus.
- The 293FT cell line, which allows production of lentivirus following cotransfection of the expression plasmid and the plasmids in the packaging mix.
- Control expression plasmid to optimize virus production and cell transduction, containing either:
    - The *lacZ* gene, which when packaged into virions and transduced into a mammalian cell line, expresses β-galactosidase (included with each expression vector kit), **or**
    - The Emerald Green Fluorescent Protein (EmGFP) gene which when packaged into virions and transduced into a mammalian cell line, expresses EmGFP (available separately, see page viii).

For more information on expression vectors and the corresponding positive control vectors, refer to the manual for the specific expression or control vector you are using.

Advantages of the System

Use of the ViraPower™ HiPerform™ Lentiviral Expression System to facilitate lentiviral-based expression of the gene of interest provides the following advantages:

- Offers you a choice to use either Gateway® technology (Catalog nos: K5310-00 and K5330-00) or TOPO® Cloning technologies (Catalog nos: K5320-00 K5340-00).
- Enhanced protein expression, up to 4-fold or greater.
- Generates an HIV-1-based lentivirus that effectively transduces both dividing and non-dividing mammalian cells, thus broadening the potential applications beyond those of traditional Moloney Leukemia Virus (MoMLV)-based retroviral systems (Naldini, 1998).
- Efficiently delivers the gene of interest to mammalian cells in culture or *in vivo* (Dull *et al.*, 1998).
- Provides stable, long-term expression of a target gene beyond that offered by traditional adenoviral-based systems (Dull *et al.*, 1998; Naldini *et al.*, 1996).
- Produces a pseudotyped virus with a broadened host range (Yee *et al.*, 1994).
- Includes multiple features designed to enhance the biosafety of the system.
- pLenti6.3 series vectors offer significantly improved levels of expression of your gene of interest by increasing the number of cells that express the cloned gene of interest (also called the Open Reading Frame, ORF).
- pLenti7.3 series vectors offer significantly improved levels of expression of your gene of interest. pLenti7.3 vectors also allow high speed and high throughput titering applications using EmGFP, and reduce the titering time down to **2 days**.

How Lentivirus Works

Once the lentivirus enters the target cell, the viral RNA is reverse-transcribed, actively imported into the nucleus (Lewis & Emerman, 1994; Naldini, 1999), and stably integrated into the host genome (Buchschacher & Wong-Staal, 2000; Luciw, 1996). After the lentiviral construct has integrated into the genome, you may assay for transient expression of your recombinant protein or use antibiotic selection to generate a stable cell line for long-term expression studies.

Purpose of this Manual

This manual provides an overview of the ViraPower™ HiPerform™ Lentiviral Expression System and provides instructions and guidelines to:

1. Co-transfect the pLenti-based expression vector and the ViraPower™ Packaging Mix into the 293FT Cell Line to produce a lentiviral stock.
2. Titer the lentiviral stock.
3. Use the lentiviral stock to transduce your mammalian cell line of choice.
4. Assay for "transient" expression of your recombinant protein, or
5. Generate a stably transduced cell line, if desired.

For details and instructions to generate your expression vector, refer to the manual for the pLenti vector you are using. For instructions to culture and maintain the 293FT producer cell line, refer to the 293FT Cell Line manual. These manuals are supplied with the ViraPower™ HiPerform™ Lentiviral Expression Kits, and are also available for downloading from www.invitrogen.com or by contacting **Technical Support** (page 40).

Biosafety Features of the System

Introduction

The ViraPower™ HiPerform™ Lentiviral Expression System is a third-generation system based on lentiviral vectors developed by Dull *et al.*, 1998. This fourth-generation lentiviral system includes a significant number of safety features designed to enhance its biosafety and to minimize its relation to the wild-type, human HIV-1 virus. These safety features are discussed below.

Biosafety Features of the ViraPower™ HiPerform™ Lentiviral System

The ViraPower™ HiPerform™ Lentiviral Expression System includes the following key safety features:

- The pLenti expression vector contains a deletion in the 3′ LTR (ΔU3) that does not affect generation of the viral genome in the producer cell line, but results in "self-inactivation" of the lentivirus after transduction of the target cell (Yee *et al.*, 1987; Yu *et al.*, 1986; Zufferey *et al.*, 1998). Once integrated into the transduced target cell, the lentiviral genome is no longer capable of producing packageable viral genome.
- The number of genes from HIV-1 that are used in the system has been reduced to three (*i.e. gag*, *pol*, and *rev*).
- The VSV-G gene from Vesicular Stomatitis Virus is used in place of the HIV-1 envelope (Burns *et al.*, 1993; Emi *et al.*, 1991; Yee *et al.*, 1994).
- Genes encoding the structural and other components required for packaging the viral genome are separated onto four plasmids. All four plasmids have been engineered not to contain any regions of homology with each other to prevent undesirable recombination events that could lead to the generation of a replication-competent virus (Dull *et al.*, 1998).
- Although the three packaging plasmids allow expression *in trans* of proteins required to produce viral progeny (*e.g.* gal, pol, rev, env) in the 293FT producer cell line, none of them contain LTRs or the Ψ packaging sequence. This means that none of the HIV-1 structural genes are actually present in the packaged viral genome, and thus, are never expressed in the transduced target cell. No new replication-competent virus can be produced.
- The lentiviral particles produced in this system are replication-incompetent and only carry the gene of interest. No other viral species are produced.
- Expression of the *gag* and *pol* genes from pLP1 has been rendered Rev-dependent by virtue of the HIV-1 RRE in the gag/pol mRNA transcript. Addition of the RRE prevents gag and pol expression in the absence of Rev (Dull *et al.*, 1998).
- A constitutive promoter (RSV promoter) has been placed upstream of the 5′ LTR in the pLenti expression vector to offset the requirement for Tat in the efficient production of viral RNA (Dull *et al.*, 1998).

Continued on next page

Biosafety Features of the System, Continued

Biosafety Level 2

Despite the inclusion of the safety features discussed on the previous page, the lentivirus produced with this System can still pose some biohazardous risk since it can transduce primary human cells. For this reason, **we highly recommend that you treat lentiviral stocks generated using this System as Biosafety Level 2 (BL-2) organisms and strictly follow all published BL-2 guidelines with proper waste decontamination.** Furthermore, exercise extra caution when creating lentivirus carrying potential harmful or toxic genes (*e.g.* activated oncogenes).

For more information about the BL-2 guidelines and lentivirus handling, refer to the document, "Biosafety in Microbiological and Biomedical Laboratories," 4th Edition, published by the Centers for Disease Control (CDC). This document may be downloaded at the following address:

http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm

Important

Handle all lentiviruses in compliance with established institutional guidelines. Since safety requirements for use and handling of lentiviruses may vary at individual institutions, we recommend consulting the health and safety guidelines and/or officers at your institution prior to use of the ViraPower™ HiPerform™ Lentiviral Expression System.

Experimental Outline

Flow Chart

The diagram below describes the general steps required to express your gene of interest using the ViraPower™ HiPerform™ Lentiviral Expression System. Refer to the appropriate manual for each pLenti expression vector for instructions to generate your pLenti expression construct.



1. Generate the pLenti expression construct containing your gene of interest.
2. Cotransfect the 293FT producer cell line with your pLenti expression construct and the optimized packaging mix.
3. Harvest viral supernatant and determine the titer.
4. Add the viral supernatant to your mammalian cell line of interest. Select for stably transduced cells, if desired.
5. Assay for recombinant protein of interest.

Methods

General Information

Introduction

The ViraPower™ HiPerform™ Lentiviral Expression System is designed to help you create a lentivirus to deliver and express a gene of interest in mammalian cells. Although the system has been designed to help you express your recombinant protein of interest in the simplest, most direct fashion, use of the system is geared towards those users who are familiar with the principles of retrovirus biology and retroviral vectors. We highly recommend that users possess a working knowledge of virus production and tissue culture techniques.

For more information about these topics, refer to the following published reviews:

- Retrovirus biology and the retroviral replication cycle: see Buchschacher and Wong-Staal (2000) and Luciw (1996).
- Retroviral and lentiviral vectors: see Naldini (1999), Naldini (1998), Yee (1999) and (Pandya *et al.*, 2001)

Positive Control

We recommend including a positive control vector in your cotransfection experiment to generate a control lentiviral stock that may be used to help you optimize expression conditions in your mammalian cell line of interest.

- Each pLenti expression vector kit includes a positive control vector for use as an expression control (*e.g.* pLenti6.3/V5-TOPO/*lacZ* or pLenti6.3/V5-GW/*lacZ*). For more information about the positive control vector supplied with each kit, refer to the appropriate expression vector manual.
- A control lentiviral expression vector containing Emerald Green Fluorescent Protein (EmGFP) for fluorescent detection (pLenti6.3/V5-GW/EmGFP) is available separately from Invitrogen (page viii).

Lipofectamine™ 2000

The Lipofectamine™ 2000 reagent supplied with the kit (Ciccarone *et al.*, 1999) is a proprietary, cationic lipid-based formulation suitable for the transfection of nucleic acids into eukaryotic cells. Using Lipofectamine™ 2000 to transfect 293FT cells offers the following advantages:

- Provides the highest transfection efficiency in 293FT cells.
- DNA-Lipofectamine™ 2000 complexes can be added directly to cells in culture medium in the presence of serum.
- Removal of complexes or medium change or addition following transfection are not required, although complexes can be removed after 4-6 hours without loss of activity.

Note: Lipofectamine™ 2000 is available separately from Invitrogen or as part of the ViraPower™ HiPerform™ Lentiviral Support Kits (see page viii).

Opti-MEM® I

To facilitate optimal formation of DNA-Lipofectamine™ 2000 complexes, we recommend using Opti-MEM® I Reduced Serum Medium available from Invitrogen (see page viii).

Generating Your pLenti Expression Construct

Introduction

To generate a pLenti expression construct containing your gene of interest, refer to your specific vector's manual for instructions. Once you have created your expression construct, isolate plasmid DNA for transfection.

Important: You should verify that your lentiviral plasmid has not undergone aberrant recombination by performing an appropriate restriction enzyme digest. See the vector manual for details.

DNA Isolation Guidelines

Plasmid DNA for transfection into eukaryotic cells must be very clean and free from contamination with phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipid complexing, decreasing transfection efficiency.

When performing plasmid DNA isolation with commercially available kits from *E. coli* strains (such as Stbl3™) that are wild type for endonuclease 1 (*end*A1+), ensure that Solution I of the Lysis or Resuspension Buffer contains 10 mM EDTA. EDTA will inactivate the endonuclease and avoid DNA nicking and vector degradation. Alternatively, follow the instructions included the plasmid purification kits for *end*A1+ *E. coli* strains.

Important

Do not use mini-prep plasmid DNA for lentivirus production. We recommend preparing lentiviral plasmid DNA using the PureLink™ HiPure Plasmid MidiPrep which contains 10 mM EDTA in the Resuspension Buffer (page viii).

Producing Lentivirus in 293FT Cells

Introduction

Before you can create a stably transduced cell line expressing your gene of interest, you will first need to produce a lentiviral stock (containing the packaged pLenti expression construct) by cotransfecting the optimized packaging plasmid mix and your pLenti expression construct into the 293FT Cell Line. This section provides protocols and instructions to generate a lentiviral stock.

ViraPower™ Packaging Mix

The pLP1, pLP2, pLP/VSVG plasmids are provided in an optimized mixture to facilitate viral packaging of your pLenti expression vector following cotransfection into 293FT producer cells. The amount of the packaging mix (195 µg) and Lipofectamine™ 2000 transfection reagent (0.75 ml) supplied in the ViraPower™ Lentiviral Expression kit is sufficient to perform 20 cotransfections in 10 cm plates.

To use the ViraPower™ Packaging Mix, resuspend the contents of one tube (195 µg) in 195 µl of sterile water to obtain a 1 µg/µl stock.

Note: ViraPower™ Packaging Mix is available separately from Invitrogen or as part of the ViraPower™ Lentiviral Support Kits (page viii).

293FT Cell Line

The human 293FT Cell Line is supplied with the ViraPower™ HiPerform™ Lentiviral Expression kits to facilitate optimal lentivirus production (Naldini *et al.*, 1996). The 293FT Cell Line, a derivative of the 293F Cell Line, stably and constitutively expresses the SV40 large T antigen from pCMVSPORT6TAg.neo and must be maintained in medium containing Geneticin® (page viii).

For more information about pCMVSPORT6TAg.neo and how to culture and maintain 293FT cells, refer to the 293FT Cell Line manual. This manual is supplied with the ViraPower™ HiPerform™ Lentiviral Expression kits, and is also available by downloading from www.invitrogen.com or by contacting **Technical Support** (page 40).

Note: The 293FT Cell Line is also available separately from Invitrogen (page viii).

The health of your 293FT cells at the time of transfection has a critical effect on the success of lentivirus production. Use of "unhealthy" cells will negatively affect the transfection efficiency, resulting in production of a low titer lentiviral stock. For optimal lentivirus production (*i.e.* producing lentiviral stocks with the expected titers), follow the guidelines below to culture 293FT cells before use in transfection:

- Ensure that cells are healthy and greater than 90% viable.
- Subculture and maintain cells in complete medium containing 0.1 mM MEM Non-Essential Amino Acids, 4 mM L-Glutamine, 1 mM sodium pyruvate, 500 µg/ml Geneticin® and 10% fetal bovine serum that is not heat-inactivated (page viii).
- Do not allow cells to overgrow before passaging.
- Use cells that have been subcultured for less than 16 passages.

Continued on next page

Recommended Transfection Conditions

We produce lentiviral stocks in 293FT cells using the following **optimized** transfection conditions in the table below. The amount of lentivirus produced using these recommended conditions (10 ml of virus at a titer of at least 1 x 10^5 transducing units (TU)/ml) is generally sufficient to transduce at least 1 x 10^6 cells at a multiplicity of infection (MOI) = 1. For example, 10 wells of cells plated at 1 x 10^5 cells/well in 6-well plates could each be transduced with 1 ml of a 1 x 10^5 TU/ml virus stock to achieve an MOI of 1.

Condition	Quantity
Tissue culture plate size	10 cm (one per lentiviral construct)
Number of 293FT cells to transfect	6 x 10^6 cells (see **Recommendation**, previous page) to prepare cells for transfection)
Amount of ViraPower™ Packaging Mix	9 µg (9 µl of 1 µg/µl stock)
Amount of pLenti expression plasmid	3 µg
Amount of Lipofectamine™ 2000	36 µl

Note: You may produce lentiviral stocks using other tissue culture formats, but keep in mind that optimization may be necessary to obtain the expected titers.

Recommended Procedure

If you are producing lentivirus for the first time using the ViraPower™ System and 293FT cells, you should perform the **Forward Transfection** procedure on page 13. This procedure requires plating the 293FT cells the day before transfection to obtain cells that are 90-95% confluent.

Note: In previous ViraPower™ manuals, this protocol was referred to as the Alternate Transfection Method.

If you are an experienced lentivirus user and are familiar with the growth characteristics of 293FT cells, you may choose to perform the **Reverse Transfection** procedure on page 14. In this procedure, 293FT cells are added to media containing the DNA-Lipofectamine™ 2000 complexes.

Continued on next page

Producing Lentivirus in 293FT Cells, Continued

Materials Needed

You will need the following items:

- pLenti expression vector containing your gene of interest (0.1-3.0 µg/µl in sterile water or TE, pH 8.0)
- 293FT cells cultured in the appropriate medium (*i.e.* D-MEM containing 10% FBS, 4 mM L-Glutamine, 1 mM MEM sodium pyruvate, 0.1 mM MEM Non-Essential Amino Acids, and 1% penicillin-streptomycin, and 500 µg/ml Geneticin®)

  Note: MEM Sodium Pyruvate provides an extra energy source for the cells and is available from Invitrogen as a 100 mM stock solution (page viii).
- Opti-MEM® I Reduced Serum Medium (pre-warmed to 37°C, page viii)
- Fetal bovine serum (FBS, page viii)
- Complete growth medium **without antibiotics** (*i.e.* D-MEM containing 10% FBS, 4 mM L-Glutamine, 0.1 mM MEM Non-Essential Amino Acids, and 1 mM MEM sodium pyruvate), pre-warmed to 37°C
- Sterile, 10 cm tissue culture plates (one each for the lentiviral construct, positive control, and negative control)
- Sterile, tissue culture supplies
- 15 ml sterile, capped, conical tubes
- Cryovials
- CO_2 humidified incubator set at 37°C
- Centrifuge capable of 2,000 x g
- **Optional:** Millex-HV 0.45 µm PVDF filters (Millipore, cat. no. SLHVR25LS) or equivalent, to filter viral supernatants
- **Optional:** pLenti control vector containing EmGFP (sold separately, page viii)

Materials Supplied with Kit

- ViraPower™ Packaging Mix (resuspend in 195 µl of sterile water to a concentration of 1 µg/µl)
- pLenti control vector containing *lacZ* (resuspended in sterile water to a concentration of 1 µg/µl)
- Lipofectamine™ 2000 transfection reagent (mix gently before use)

Continued on next page

Forward Transfection Procedure

If you are a **first time user**, follow the procedure below to cotransfect 293FT cells. For information on positive controls, see page 8. We recommend including a negative control (no DNA, no Lipofectamine™ 2000) in your experiment to help you evaluate your results.

1. The day before transfection (Day 1), plate 293FT cells in a 10 cm tissue culture plate so that they will be 90-95% confluent on the day of transfection (*i.e.* 5 x 10^6 cells in 10 ml of growth medium containing serum). **Do not include antibiotics in the medium.** Incubate cells overnight at 37°C in a humidified 5% CO_2 incubator.
2. On the day of transfection (Day 2), remove and discard the culture medium from the 293FT cells and replace with 5 ml of growth medium (Opti-MEM® I Medium, page viii) containing serum. **Do not use antibiotics in the medium.**
3. **For each transfection sample**, prepare DNA-Lipofectamine™ 2000 complexes as follows:
   a. In a sterile 5 ml tube, dilute 9 µg of the ViraPower™ Packaging Mix and 3 µg of your pLenti expression plasmid DNA (12 µg total) in 1.5 ml of Opti-MEM® I Medium without serum. Mix gently.
   b. In a separate, sterile 5 ml tube, dilute 36 µl Lipofectamine™ 2000 (mix gently before use) in 1.5 ml of Opti-MEM® I Medium without serum. Mix gently and incubate for 5 minutes at room temperature.
   c. After incubation, combine the diluted DNA (Step a) with the diluted Lipofectamine™ 2000 (Step b). Mix gently.
   d. Incubate for 20 minutes at room temperature to allow the DNA-Lipofectamine™ 2000 complexes to form. The solution may appear cloudy, but this will not impede the transfection.
4. Add all the DNA-Lipofectamine™ 2000 complexes dropwise to the plate of 293FT cells (Steps 1 and 2). Mix gently by rocking the plate back and forth. Incubate the cells overnight at 37°C in a humidified 5% CO_2 incubator.
5. The next day (Day 3), remove the cell culture plate containing the 293FT cells with DNA-Lipofectamine™ complexes from the incubator. Remove and discard the medium containing the DNA-Lipofectamine™ 2000 complexes and replace with 10 ml complete culture medium **without antibiotics**.
6. Incubate cells for 48-72 hours at 37°C in a humidified 5% CO_2 incubator. (Minimal differences in viral yield are observed whether supernatants are collected at either 48 or 72 hours post-transfection).

   Note: Expression of the VSV G glycoprotein causes 293FT cells to fuse, resulting in the appearance of large, multinucleated cells known as syncytia. This morphological change is normal and does not affect production of the lentivirus.
7. Post-transfection (Day 5 or 6), harvest virus-containing supernatants by removing and transferring the medium into a 15 ml sterile, capped, conical tube.

   Caution: Remember that you are working with infectious virus at this stage. Follow recommended guidelines for working with BL-2 organisms (refer to page 5).
8. Centrifuge supernatants at 2,000 x g for 15 minutes at +4°C to pellet debris.
9. *Optional:* Filter the viral supernatants through a Millex-HV 0.45 µm or equivalent PVDF filter (see **Note**, page 15).
10. Pipet viral supernatants into cryovials in 1 ml aliquots.
11. Store viral stocks at -80°C. Proceed to **Titering Your Lentiviral Stock**, page 16.

Continued on next page

Reverse Transfection Procedure

If you are an **experienced user**, you may use the rapid, reverse transfection procedure to cotransfect 293FT cells. For information on positive controls, see page 8. We recommend including a negative control (no DNA, no Lipofectamine™ 2000) in your experiment to help you evaluate your results. You will need 6 x 10^6 293FT cells for each sample.

1. On Day 1, prepare DNA-Lipofectamine™ 2000 complexes **for each transfection sample** as follows:
   a. In a sterile 5 ml tube, dilute 9 µg of the ViraPower™ Packaging Mix and 3 µg of pLenti expression plasmid DNA (12 µg total) in 1.5 ml of Opti-MEM® I Medium without serum. Mix gently.
   b. In a separate sterile 5 ml tube, dilute 36 µl Lipofectamine™ 2000 (mix gently before use) in 1.5 ml of Opti-MEM® I Medium without serum. Mix gently and incubate for 5 minutes at room temperature.
   c. After incubation, combine the diluted DNA (Step a) with the diluted Lipofectamine™ 2000 (Step b). Mix gently.
   d. Incubate for 20 minutes at room temperature to allow the DNA-Lipofectamine™ 2000 complexes to form. The solution may appear cloudy, but this will not impede the transfection.
2. While DNA-lipid complexes are forming, trypsinize and count the 293FT cells. Resuspend the cells at a density of 1.2 x 10^6 cells/ml in growth medium (or Opti-MEM® I Medium) containing serum. **Do not include antibiotics in the medium.**
3. Add the DNA-Lipofectamine™ 2000 complexes (Step 1d) to a 10 cm tissue culture plate containing 5 ml of growth medium (or Opti-MEM® I Medium) containing serum. **Do not include antibiotics in the medium.**
4. Add 5 ml of the 293FT cell suspension from Step 2 (6 x 10^6 total cells) to the plate containing media and DNA-Lipofectamine™ 2000 complexes (Step 3). Mix gently by rocking the plate back and forth. Incubate cells overnight at 37°C in a humidified 5% CO_2 incubator.
5. The next day (Day 2), remove and discard the medium containing the DNA-Lipofectamine™ 2000 complexes and replace with 10 ml complete culture medium **without antibiotics**.
6. Incubate cells for 48-72 hours at 37°C in a humidified 5% CO_2 incubator. (Minimal differences in viral yield are observed whether supernatants are collected at either 48 or 72 hours posttransfection)

   Note: Expression of the VSV G glycoprotein causes 293FT cells to fuse, resulting in the appearance of large, multinucleated cells known as syncytia. This morphological change is normal and does not affect production of the lentivirus.
7. Posttransfection (Day 4 or 5), harvest virus-containing supernatants by removing and placing the medium into a 15 ml sterile, capped, conical tube.

   Caution: Remember that you are working with infectious virus at this stage. Follow recommended guidelines for working with BL-2 organisms (refer to page 5).
8. Centrifuge supernatants at 2,000 x g for 15 minutes at +4°C to pellet debris.
9. **Optional:** Filter the viral supernatants through a Millex-HV 0.45 µm or equivalent PVDF filter (see **Note**, next page).
10. Pipet viral supernatants into cryovials in 1 ml aliquots.
11. Store viral stocks at -80°C. Proceed to **Titering Your Lentiviral Stock**, page 16.

Continued on next page

Note

It should be possible to use the new ViraPower™ HiPerform™ Lentiviral vector constructs for *in vivo* applications, however, we have not yet tested the new constructs *in vivo*.

If you plan to use your lentiviral construct for *in vivo* applications, we recommend filtering your viral supernatant through a sterile, 0.45 µm low protein binding filter after the low-speed centrifugation step (Step 8, previous page) to remove any remaining cellular debris. We recommend using Millex-HV 0.45 µm PVDF filters (Millipore, Catalog no. SLHVR25LS) for filtration.

If you wish to concentrate your viral stock to obtain a higher titer, perform the filtration step first before concentrating your viral stock.

Concentrating Virus

It is possible to concentrate VSV-G pseudotyped lentiviruses using a variety of methods without significantly affecting their ability to transduce cells. If your cell transduction experiment requires that you use a relatively high Multiplicity of Infection (MOI), you may wish to concentrate your virus before titering and proceeding to transduction. For details and guidelines to concentrate your virus supernatant by ultracentrifugation, refer to published reference sources (Yee, 1999).

Long-Term Storage

Store viral stocks at -80°C in cryovials for long-term storage. Repeated freezing and thawing is not recommended as it may result in loss of viral titer. When stored properly, viral stocks of an appropriate titer should be suitable for use for up to one year. After long-term storage, we recommend retitering your viral stocks before transducing your mammalian cell line of interest.

Scaling Up Virus Production

It is possible to scale up the cotransfection experiment to produce a larger volume of lentivirus, if desired. For example, we have scaled up the cotransfection experiment from a 10 cm plate to a T-175 cm^2 flask and harvested up to 30 ml of viral supernatant. If you wish to scale up your cotransfection, remember that you will need to increase the number of cells plated and the amounts of DNA, Lipofectamine™ 2000, and medium used in proportion to the difference in surface area of the culture vessel.

Titering Your Lentiviral Stock

Introduction

Before proceeding to transduction and expression experiments, we highly recommend determining the titer of your lentiviral stock. While this procedure is not required for some applications, it is necessary if:

- You wish to control the number of integrated copies of the lentivirus
- You wish to generate reproducible expression results

Guidelines and protocols are provided in this section to titer your lentiviral stock.

In addition to higher expression of the gene of interest, all ViraPower™ HiPerform™ Lentiviral vectors yield a higher Blasticidin (Bsd) or Emerald Green Fluorescence (EmGFP) titer compared to previous pLenti vectors. The pLenti6.3 vectors (K5310-00 and K5330-00) contain Bsd in the vector backbone, which allows titer of active virus by selection of Blasticidin resistant clones after transduction. Alternatively, pLenti7.3 FastTiter™ vectors (K5320-00 and K5340-00) contain the EmGFP reporter gene in the vector backbone which allows titer by flow cytometry in only **2 days** post-transduction.

For **Titering lentiviral stock using EmGFP**, refer to page 18.

For **Titering lentiviral stock using Blasticidin**, refer to page 22.

ViraPower™ HiPerform™ Lentiviral FastTiter™ Expression Kits

ViraPower™ HiPerform™ Lentiviral FastTiter™ Expression kits (K5320-00 and K5340-00) allow you to titer lentivirus in only **2 days** because the pLenti7.3 vectors contain EmGFP reporter gene in the vector backbone, instead of Bsd. This feature makes these kits ideal for high-throughput and quick-screens of transient expression using flow cytometry.

Important: The FastTiter™ Expression kits are optimal for quick-screens of transient expressions using flow cytometry. The signal intensity produced by these kits is **not** optimal for detection using fluorescence microscopy. We recommend flow cytometry to detect the EmGFP in your transduced cells.

Factors Affecting Viral Titer

A number of factors can influence viral titers including:

- **The size of your gene of interest.** Titers will decrease as the size of the insert increases. We have determined that virus titer drops approximately 2-fold for each kb over 4 kb of insert size. If you wish to produce lentivirus with an insert of > 4 kb, you will need to concentrate the virus to obtain a suitable titer (see page 15). The size of the wild-type HIV genome is approximately 10 kb. Since the size of the elements required for expression from pLenti vectors total approximately 4-4.4 kb, the size of your insert should not exceed 5.6 kb.
- **The characteristics of the cell line used for titering**- We strongly recommend the human fibrosarcoma line HT1080 as the "gold standard" for reproducibly titering lentivirus. However, other cell lines may be used. In general, these cells should be an adherent, non-migratory cell line, and exhibit a doubling time in the range of 18-25 hours.
- **The age of your lentiviral stock-** Viral titers may decrease with long-term (>1 year) storage at -80°C. If your lentiviral stock has been stored for longer than 6 months, we recommend titering your lentiviral stock prior to use.
- **Number of freeze/thaw cycles-** Viral titers can decrease as much as 10% with each freeze/thaw cycle.
- **Improper storage of your lentiviral stock-** Lentiviral stocks should be stored at -80°C in cryovials.

Continued on next page

Titering Your Lentiviral Stock, Continued

Selecting a Cell Line for Titering

We strongly recommend the human fibrosarcoma line HT1080 (ATCC, cat no. CCL-121) as the "gold standard" for reproducibly titering lentivirus. However, you may wish to use the same mammalian cell line to titer your lentiviral stocks as you will use to perform your expression studies (*e.g.* if you are performing expression studies in a dividing cell line or a non-primary cell line). If you have more than one lentiviral construct, we recommend that you titer all of the lentiviral constructs using the same mammalian cell line. For more information on cells for titering, see **Factors Affecting Viral Titer**, previous page.

Using Polybrene® During Transduction

Lentivirus transduction may be enhanced if cells are transduced in the presence of hexadimethrine bromide (Polybrene®, Sigma, Catalog no. H9268). For best results, we recommend performing transduction in the presence of Polybrene®. Note however, that some cells are sensitive to Polybrene® (*e.g.* primary neurons). Before performing any transduction experiments, you may want to test your cell line for sensitivity to Polybrene® at a range of 0-10 µg/ml. If your cells are sensitive to Polybrene® (*e.g.* exhibit toxicity or phenotypic changes), do not add Polybrene® during transduction. In this case, cells should still be successfully transduced with your lentivirus.

Preparing and Storing Polybrene®

Follow the instructions below to prepare Polybrene®:

1. Prepare a 6 mg/ml stock solution in deionized, sterile water.
2. Filter-sterilize and dispense 1 ml aliquots into sterile microcentrifuge tubes.
3. The working stock may be stored at +4°C for up to 2 weeks. Store at -20°C for long-term storage (up to 1 year). Do not freeze/thaw the stock solution more than 3 times as this may result in loss of activity.

Titering Your Lentiviral Stock Using EmGFP

Introduction

Guidelines and protocols for titering your lentiviral stock using Emerald Green Fluorescence (EmGFP) are provided in this section.

If you wish to titer your lentiviral stock using Blasticidin, refer to page 22.

Remember that you are working with media containing infectious virus. Follow the recommended Federal and institutional guidelines for working with BL-2 organisms.

- Perform all manipulations within a certified biosafety cabinet.
- Treat media containing virus with bleach.
- Treat used pipettes, pipette tips, and other tissue culture supplies with bleach and dispose of as biohazardous waste.
- Wear gloves, a laboratory coat, and safety glasses or goggles when handling viral stocks and media containing virus.

Experimental Outline

To determine the titer of your EmGFP lentiviral stocks, you will:

1. Prepare a 50-fold or 20-fold serial dilutions of your lentiviral stocks.
2. Transduce the different dilutions of lentivirus in the presence of the polycation Polybrene® (page 17).
3. Determine the Lentiviral titer by fluorescence detection using flow cytometry at 2 days post-transduction, see **Important**, below.

Important

We do not recommend the use of fluorescence microscopy for detecting EmGFP in your cells from the pLenti7.3 vectors. The pLenti7.3 vectors are designed with EmGFP in their vector backbone which allows for quick-screens of transient expression in your cells and titering times of only 2-days. While the quantity of cells expressing your gene of interest is significantly greater than other pLenti vectors that do not contain the WPRE and cPPT elements, the signal intensity of EmGFP expressed in your cells is not optimal for viewing with fluorescence microscopy. For this reason, we recommend flow cytometry.

Continued on next page

Titering Your Lentivirus Stock Using EmGFP, Continued

Materials Needed

You will need the following items:

- Your EmGFP lentiviral stock from either the pLenti7.3/V5-TOPO® vector or the pLenti7.3/V5-DEST Gateway® vector (store at -80°C until use)
- Adherent mammalian cell line of choice
- Complete culture medium for your cell line
- 6 mg/ml Polybrene®, (*optional*, see page 17)
- 96-well tissue culture plates
- Optional: TrypLE (page viii)
- Tripsin cell dissociation solution using , see below (or equivalent) for flow cytometry
- *Optional:* Flow cytometry buffer of choice, such as calcium/magnesium-free Phosphate Buffered Saline containing 1% FBS or BSA.

Trypsin Dissociation Solution

Before proceeding to analysis with flow cytometry, you need to dissociate your cells from the wells. To prepare the dissociation solution using TrypLE:

1. Make a 1:3 mix of TrypLE and PBS, respectively (see page viii to order).
2. Add 25 µl of a 1 mg/ml propidium iodide stock solution (page viii).

Transduction and Titering Procedure for EmGFP

Follow the procedure below to determine the titer of your lentiviral stock using the mammalian cell line of choice. You will use at least one 6-well plate for each lentiviral stock to be titered (usually one mock well plus five dilutions).

1. **24 hours before transduction**, seed cells in a 96-well format at a density of 6,000 cells per well. Incubate in a 37°C CO_2 incubator overnight.
2. On the day of transduction (Day 1), thaw your lentiviral stock. In a biosafety cabinet, prepare a 50-fold or 20-fold serial dilution of the Lentiviral stock in DMEM growth medium supplemented with polybrene (page 17). Mix each virus dilution gently by inversion (**DO NOT** vortex).

   Important: Do **NOT** dilute virus in culture medium containing Blasticidin.
3. Remove the culture medium from each well of cells and replace with the diluted virus solution. We recommend allocating 3-6 replicate wells per sample.
4. Swirl the plate gently to mix. Incubate at 37°C in a CO_2 incubator overnight.
5. After 24 hours incubation (Day 2), remove the virus-containing media from each well and discard (See **Caution**, previous page). Replace with 100 µl of fresh growth medium in each well and incubate overnight in a 37°C CO_2 incubator.

   Important: Do **NOT** add Blasticidin to the growth medium.
6. After 24 hours incubation (Day 3), remove the growth media from each well and discard. Replace with dissociation solution (above) in each well.
7. Allow cells to dissociate for 5 minutes at 37°C then proceed **Preparing Cells for Flow Cytometry**, next page (see **Important**, previous page).

Continued on next page

Titering Your Lentiviral Stock Using EmGFP, Continued

Note

If you wish to fix your cells before flow cytometry, you can use 2% formaldehyde or paraformaldehyde in calcium/magnesium free PBS. However these fixatives may increase autofluorescence of the cells, thus it is critical to include fixed, mock-transduced cells as a negative control for flow cytometry detection parameters.

Preparing Cells for Flow Cytometry

Prepare cells for flow cytometry using a FITC filter according to the established protocols in use at your flow cytometry facility. The steps below provide simple guidelines, and other methods may be suitable.

1. After cell dissociation (Steps 6-7, previous page) spin cells at 2,000 x g in a centrifuge to remove residual media components and resuspend the cell pellet in flow cytometry buffer such as calcium/magnesium free PBS with 1% FBS at the required density for analysis on your flow cytometer. Fixing the cells is not necessary but may be done (see **Note** above).
2. Use the mock-transduced cells and the lowest dilution of virus (*i.e.* 10^{-1}) as the negative and positive samples, respectively, to set up the parameters of your flow cytometer.

Continued on next page

Titering Your Lentiviral Stock Using EmGFP, Continued

Calculating Lentiviral Titer for EmGFP

EmGFP lentivirus titers should be calculated from the dilutions at which the percentage of GFP-positive cells fall within the range of 1-30% (White *et al.*, 1999) (Sastry *et al.*, 2002). This is to avoid analyzing dilution samples containing multiple integrated lentiviral genomes, which may result in an underestimate of the viral titer, or dilution samples containing too few transduced cells, which will give inaccurate results. Titer is expressed as transducing units (TU)/ml.

1. In the following example, an EmGFP lentiviral stock was generated using the protocol on the previous page. The stock was concentrated and the following data were generated after performing flow cytometry:

Lentivirus Dilution	% EmGFP Positive Cells
10^{-2}	91.5%
10^{-3}	34.6%
10^{-4}	4.4%

The following formula (White *et al.*, 1999) (Sastry *et al.*, 2002) is used to calculate the titer:

$[F \times C/V] \times D$

F = frequency of GFP-positive cells (percentage obtained divided by 100)

C = total number of cells in the well at the time of transduction

V = volume of inoculum in ml

D = lentivirus dilution

In the above example, the 10^{-4} dilution is used to calculate the titer since the percentage of EmGFP-positive cells falls into the desired range of 1-30%. The frequency of EmGFP-positive cells is 4.4/100 = 0.044, multiplied by 2×10^5 (the number of cells in the well) divided by 1 (the volume of inoculum). Thus the calculation is as follows:

$$[(0.044 \times 200{,}000)/1] \times 10^4$$

The titer for this example is 8.8×10^7 TU/ml.

What You Can Expect

We typically obtain unconcentrated EmGFP lentivirus titers in the range of 5×10^5 - 2×10^6 TU/ml. To obtain higher lentivirus titer, you can concentrate your virus (see page 15). The titer of concentrated lentivirus stocks may be up to 1×10^8 TU/ml.

Titering Your Lentiviral Stock Using Blasticidin

Introduction

Guidelines and protocols for titering your lentiviral stock using Blasticidin (page viii) are provided in this section.

If you wish to titer your lentiviral stock using EmGFP, refer to page 18.

Remember that you are working with media containing infectious virus. Follow the recommended Federal and institutional guidelines for working with BL-2 organisms.

- Perform all manipulations within a certified biosafety cabinet.
- Treat media containing virus with bleach.
- Treat used pipettes, pipette tips, and other tissue culture supplies with bleach and dispose of as biohazardous waste.
- Wear gloves, a laboratory coat, and safety glasses or goggles when handling viral stocks and media containing virus.

Experimental Outline

To determine the titer of your lentiviral stocks using Blasticidin, you will:

1. Prepare 10-fold serial dilutions of your lentiviral stocks.
2. Transduce the different dilutions of lentivirus in the presence of the polycation Polybrene® into a mammalian cell line (HT1080 is recommended).
3. Select for stably transduced cells using Blasticidin.
4. Stain and count the number of Blasticidin-resistant colonies in each dilution.

Antibiotic Selection

The pLenti6.3 expression constructs contain the Blasticidin resistance gene (*bsd*) (Kimura *et al.*, 1994) to allow for Blasticidin selection (Takeuchi *et al.*, 1958; Yamaguchi *et al.*, 1965) of mammalian cells that have stably transduced the lentiviral construct.

Blasticidin is supplied with the ViraPower™ HiPerform™ Lentiviral Expression Kit, but you can also purchase Blasticidin separately from Invitrogen (page viii).

Preparing Blasticidin

For more information about how to prepare and handle Blasticidin, refer to the **Appendix** (page 33).

Continued on next page

Titering Your Lentiviral Stock Using Blasticidin, Continued

Determining Antibiotic Sensitivity

Since you will be selecting for stably transduced cells using Blasticidin, you must first determine the minimum concentration of Blasticidin required to kill your untransduced mammalian cell line (*i.e.* perform a kill curve experiment). Typically, concentrations ranging from 2-10 µg/ml Blasticidin are sufficient to kill most untransduced mammalian cell lines. We recommend that you test a range of concentrations (see protocol below) to ensure that you determine the minimum concentration necessary for your cell line.

1. Plate cells at approximately 25% confluence. Prepare a set of 6-7 plates. Allow cells to adhere overnight.
2. The next day, substitute culture medium with medium containing varying concentrations of Blasticidin, as appropriate.
3. Replenish the selective media every 3-4 days, and observe the percentage of surviving cells.
4. Determine the appropriate concentration of Blasticidin that kills the cells within 10-14 days after addition of antibiotic.

Materials Needed

You will need the following items:

- Your pLenti lentiviral stock from either the pLenti6.3/V5-TOPO® vector or pLenti6.3/V5-DEST Gateway® vector (store at -80°C until use)
- Adherent mammalian cell line of choice
- Complete culture medium for your cell line
- 6 mg/ml Polybrene®, (*optional*, see page 17)
- 6-well tissue culture plates
- Blasticidin (10 mg/ml stock), as appropriate for selection (supplied with kit)
- Crystal violet (Sigma, Catalog no. C3886; prepare a 1% crystal violet solution in 10% ethanol)
- Phosphate-Buffered Saline (PBS; page viii)

Continued on next page

Transduction and Titering Procedure Blasticidin

Follow the procedure below to determine the titer of your lentiviral stock using the mammalian cell line of choice. You will use **at least** one 6-well plate for every lentiviral stock to be titered (one mock well plus five dilutions).

1. The day before transduction, trypsinize and count the cells, plating cells in a 6-well plate at a density of 2×10^5 cells per well, such that they will be 30-50% confluent at the time of transduction. Incubate cells at 37°C overnight in a humidified 5% CO_2 incubator.

   Example: When using HT1080 cells, we usually plate 2×10^5 cells per well in a 6-well plate.
2. On the day of transduction (Day 1), thaw your lentiviral stock and prepare 10-fold serial dilutions ranging from 10^{-2} to 10^{-6}. For each dilution, dilute the lentiviral stock into complete culture medium to a final volume of 1 ml. **DO NOT** vortex.

   Note: You may prepare a wider range of serial dilutions (10^{-2} to 10^{-8}), if desired.
3. Remove the culture medium from the cells. Mix each dilution gently by inversion and add to one well of cells (total volume = 1 ml).
4. Add Polybrene® (if desired, see page 17) to each well to a final concentration of 6 µg/ml. Swirl the plate gently to mix. Incubate at 37°C overnight in a humidified 5% CO_2 incubator.
5. The following day (Day 2), remove the media containing virus and replace with 2 ml of complete culture medium. Incubate at 37°C overnight in a humidified 5% CO_2 incubator.
6. The following day (Day 3), remove the medium and replace with complete culture medium containing the appropriate amount of Blasticidin to select for stably transduced cells.
7. Replace medium with fresh medium containing antibiotic every 4-5 days.
8. After 10-12 days of selection (day 14-16), you should see no live cells in the mock well and discrete antibiotic-resistant colonies in one or more of the dilution wells. Remove the medium and wash the cells twice with PBS.
9. Add crystal violet solution (1 ml for 6-well dish; 5 ml for 10 cm plate) and incubate for 10 minutes at room temperature.
10. Remove the crystal violet stain and wash the cells with PBS. Repeat wash.
11. Count the blue-stained colonies and determine the titer of your lentiviral stock.

Continued on next page

Titering Your Lentiviral Stock Using Blasticidin, Continued

What You Should See

When titering pLenti lentiviral stocks using HT1080 cells, we generally obtain titers ranging from 1 - 5 x 10^5 (for unconcentrated virus) up to 2 x 10^7 (for concentrated virus) transducing units (TU)/ml.

Example of Expected Results

In this experiment, a Lenti6.3/V5-GW/*lacZ* lentiviral stock was generated using the protocol on page 13 and was concentrated by ultracentrifugation. HT1080 cells were transduced with 10-fold serial dilutions of the lentiviral supernatant (10^{-2} to 10^{-6} dilutions) or untransduced (mock) following the protocol on page 24. At 48 hours post-transduction, the cells were placed under Blasticidin selection (10 µg/ml). After 10 days of selection, the cells were stained with crystal violet (see plate below), and colonies were counted.



In the plate above, the colony counts were:

- Mock: no colonies
- 10^{-2} dilution: confluent; undeterminable
- 10^{-3} dilution: confluent; undeterminable
- 10^{-4} dilution: confluent; undeterminable
- 10^{-5} dilution: 46
- 10^{-6} dilution: 5

Thus, the titer of this concentrated lentiviral stock is 4.8 x 10^6 TU/ml (*i.e.* average of 46 x 10^5 and 5 x 10^6).

Next Steps

It is important to note that user experience, the nature of the gene, and vector backbone may affect virus titer. If the titer of your unconcentrated virus is suitable (*i.e.* 1 × 10^5 TU/ml or higher), proceed to **Transduction of Cells With Lentivirus**. If the titer of your concentrated lentiviral stock is less than 1 × 10^5 TU/ml, we recommend producing a new lentiviral stock. See **Troubleshooting** (page 30) for more tips and guidelines to optimize your viral yield.

Transduction and Analysis

Introduction

Once you have generated a lentiviral stock with a suitable titer, you are ready to transduce the lentiviral construct into the mammalian cell line of choice and assay for expression of your recombinant protein. Guidelines are provided below.

Important

Your lentiviral construct contains a deletion in the 3′ LTR that leads to self-inactivation of the lentivirus after transduction into mammalian cells. Once integrated into the genome, the lentivirus can no longer produce packageable virus.

Transient vs. Stable Expression

After transducing your lentiviral construct into the mammalian cell line of choice, you may assay for expression of your gene of interest in the following ways:

- For pLenti6.3 and pLenti 7.3 vectors, pool a heterogeneous population of cells and test for expression directly after transduction (*i.e.* "transient" expression). Note that you must wait for a minimum of 48-72 hours after transduction before harvesting your cells to allow expressed protein to accumulate in transduced cells.
- For pLenti6.3 vectors **only**, select for stably transduced cells using Blasticidin. This requires a minimum of 10-12 days after transduction, but allows generation of clonal cell lines that stably express the gene of interest. Please be aware that the pLenti7.3 vectors are used for transient expression only and do not produce stably transduced cells.

  Note: We have observed stable expression of a target gene for at least 6 weeks following transduction and selection.

Multiplicity of Infection (MOI)

To obtain optimal expression of your gene of interest, you will need to transduce the lentiviral construct into your mammalian cell line of choice using a suitable MOI. MOI is defined as the number of virus particles per cell and generally correlates with the number of integration events and as a result, expression of your gene of interest. Typically, expression levels increase linearly as the MOI increases.

Determining the Optimal MOI

A number of factors can influence optimal MOI including the nature of your mammalian cell line (*e.g.* non-dividing vs. dividing cell type; see **Recommendation** on the next page), its transduction efficiency, your application of interest, and the nature of your gene of interest. If you are transducing your lentiviral construct into the mammalian cell line of choice for the first time, we recommend using a range of MOI (*e.g.* 0, 0.5, 1, 2, 5, 10) to determine the MOI required to obtain the optimal expression of your protein for your application.

Continued on next page

In general, we have found that 80-90% of the cells in an actively dividing cell line (*e.g.* HT1080) express a target gene when transduced at an MOI of ~1. Some non-dividing cell types transduce lentiviral constructs less efficiently. For example, only about 50% of the cells in a culture of primary human fibroblasts express a target gene when transduced at an MOI of ~1. If you are transducing your lentiviral construct into a non-dividing cell type, you may need to increase the MOI (*e.g.* MOI = 10) to achieve optimal expression levels for your recombinant protein.

Positive Control

Control lentiviral vectors expressing *lacZ* are available for optimization (see your vector manual and page viii for information). If you have generated a lentiviral stock of a *lacZ* expression control (pLenti6.3/V5-GW/*lacZ* or pLenti6.3/V5-GW/EmGFP), we recommend using the stock to help you determine the optimal MOI for your particular cell line and application. Once you have transduced the control lentivirus into your mammalian cell line of choice, the gene encoding β-galactosidase will be constitutively expressed and can be easily assayed (refer to the expression vector or expression control vector manual for assay methods).

Note

Viral supernatants are generated by harvesting spent media containing virus from the 293FT producer cells. Spent media lacks nutrients and may contain some toxic metabolic waste products. If you are using a large volume of viral supernatant to transduce your mammalian cell line (*e.g.* 1 ml of viral supernatant per well in a 6-well plate), note that growth characteristics or morphology of the cells may be affected during transduction. These effects are generally alleviated after transduction when the media is replaced with fresh, complete media.

Materials Needed

You will need the following items:

- Your titered lentiviral stock, page 16 (store at -80°C until use)
- Mammalian cell line of choice
- Complete culture medium for your cell line
- 6 mg/ml Polybrene®, if desired (page 17)
- Appropriately sized tissue culture plates for your application
- Blasticidin, as appropriate (if selecting for stably transduced cells, **pLenti6.3 vectors only**)

Continued on next page

Transduction Procedure for Blasticidin

Follow the procedure below to transduce the mammalian cell line of choice using the pLenti6.3 vectors.

1. Plate cells in complete media as appropriate for your application.
2. On the day of transduction (Day 1), thaw your lentiviral stock, and if necessary, dilute the appropriate amount of virus into fresh complete medium to obtain a suitable MOI. Keep the total volume of medium containing virus as low as possible to maximize transduction efficiency. Do **not** vortex.
3. Remove the culture medium from the cells. Mix the medium containing virus gently by pipetting and add to the cells.
4. Add Polybrene® (if desired) to a final concentration up to 10 µg/ml. Swirl the plate gently to mix. Incubate at 37°C in a humidified 5% CO_2 incubator overnight.

   Note: If you are transducing cells with undiluted viral stock and are concerned about possible toxicity or growth effects caused by overnight incubation, it is possible to incubate cells for as little as 6 hours prior to changing medium.
5. The following day (Day 2), remove the medium containing virus and replace with fresh, complete culture medium. Incubate at 37°C in a humidified 5% CO_2 incubator overnight.
6. The following day (Day 3), perform one of the following:
   - Harvest the cells and assay for expression of your recombinant protein if you are performing transient expression experiments.
   - Remove the medium and replace with fresh, complete medium containing the appropriate amount of Blasticidin to select for stably transduced cells. Proceed to Step 7.
7. Replace medium with fresh medium containing antibiotic every 3-4 days until antibiotic-resistant colonies can be identified (generally 10-12 days after selection).
8. Pick at least 5 antibiotic-resistant colonies (see **Note,** below) and expand each clone to assay for expression of the recombinant protein.

Note

Integration of the lentivirus into the genome is random. Depending upon the influence of the surrounding genomic sequences at the integration site, you may see varying levels of recombinant protein expression from different antibiotic-resistant clones. We recommend testing at least 5 antibiotic-resistant clones and selecting the clone that provides the optimal expression of your recombinant protein for further studies.

Detecting Recombinant Protein

You may use any method of choice to detect your recombinant protein of interest including functional analysis, immunofluorescence, or western blot. If you have cloned your gene of interest in frame with an epitope tag, you may easily detect your recombinant protein in a western blot using an antibody to the epitope tag (see your lentiviral vector manual for details).

Transduction Procedure for EmGFP

Follow the procedure below to transduce the mammalian cell line of choice using the pLenti7.3 vectors.

1. Plate cells in complete media as appropriate for your application.
2. On the day of transduction (Day 1), thaw your lentiviral stock and dilute (if necessary) the appropriate amount of virus (see **Determining Optimal MOI**, page 26) into fresh complete medium. Keep the total volume of medium containing virus as low as possible to maximize transduction efficiency.
3. Remove the culture medium from the cells. Mix the medium containing virus gently by pipetting (**DO NOT** vortex) and add to the cells.
4. Add Polybrene® (if desired) to the plate a final concentration of 6 µg/ml. Swirl the plate gently to mix. Incubate at 37°C in a CO_2 incubator overnight.

   Note: If you are transducing cells with undiluted viral stock and are concerned about possible toxicity or growth effects caused by overnight incubation, it is possible to incubate cells for as little as 6 hours prior to changing medium.
5. The following day (Day 2), remove the medium containing virus and replace with fresh, complete culture medium **without** Blasticidin.
6. The following day (Day 3), you may analyze the cells for expression of EmGFP by flow cytometry (see **Important,** page 18)
7. You may sort the cells expressing EmGFP with flow cytometry and use these cells for assaying protein expression

Note: pLenti7.3 vectors do not contain an antibiotic selection marker and therefore, do not generate antibiotic resistant clones. Although your gene of interest is integrated into the lentiviral genome, there is no antibiotic selection pressure maintaining the integrity of the expression construct. As a result, depending on the influence of surrounding genomic sequences, your construct may change over the course of multiple passages, resulting in reduction or loss of protein expression.

Troubleshooting

Generating the Lentiviral Stock

The table below lists some potential problems and possible solutions that may help you troubleshoot your cotransfection and titering experiments.

Problem	Reason	Solution
Low viral titer	Low transfection efficiency: • Used poor quality expression construct plasmid DNA (*i.e.* plasmid DNA from a mini-prep) • Unhealthy 293FT cells; cells exhibit low viability • Cells transfected in media containing antibiotics (*i.e.* Geneticin®) • Plasmid DNA:transfection reagent ratio incorrect • Insufficient co-transfection • 293FT cells plated too sparsely	 • **Do not** use mini-prep plasmid DNA for transfection. Use the PureLink™ HiPure Plasmid Midiprep kti or CsCl gradient centrifugation to prepare plasmid DNA. • Use healthy 293FT cells under passage 16; do not overgrow. • Although Geneticin® is required for stable maintenance of 293FT cells, **Do not** add Geneticin® to media during transfection as this reduces transfection efficiency and causes cell death. • Use a DNA (in µg):Lipofectamine™ 2000 (in µl) ratio ranging from 1:2 to 1:3. • Use more DNA/ Lipofectamine™ 2000 (keeping the ratios the same). For example, use 5 µg of lentiviral vector, 15 µg of packaging mix, and 60 µl of Lipofectamine™ 2000 for transfection. • Plate cells such that they are 90-95% confluent at the time of transfection **or** use the Reverse Transfection protocol (*i.e.* add cells to media containing DNA-lipid complexes; see page 14).
	Transfected cells not cultured in media containing sodium pyruvate	One day after transfection, remove media containing DNA-lipid complexes and replace with media containing sodium pyruvate. Sodium pyruvate provides an extra energy source for the cells.
	Viral supernatant harvested too early	Viral supernatants can generally be collected 48-72 hours posttransfection. If many cells are still attached to the plate and look healthy at this point, wait an additional 24 hours before harvesting the viral supernatant. Harvest no later than 72 hours post-transfection.
	Viral supernatant too dilute	Concentrate your virus (Yee, 1999).
	Viral supernatant frozen and thawed multiple times	Do **not** freeze/thaw viral supernatant more than 3 times.
	Poor choice of titering cell line	Use HT1080 cells or another adherent cell line with the characteristics discussed on page 17.

Continued on next page

Generating the Lentiviral Stock, continued

Problem	Reason	Solution
Low viral titer, continued	Gene of interest is toxic to cells	Do not generate constructs containing activated oncogenes or harmful genes.
	Gene of interest is large	Viral titers generally decrease as the size of the insert increases. Concentrate the virus if titer is low (see page 15) Inserts larger than 5.6 kb are not recommended.
	Polybrene® not included during transduction	Transduce the lentiviral construct into cells in the presence of Polybrene®.
	Lipofectamine™ 2000 handled incorrectly	• Store at +4°C. **Do not freeze.** • Mix gently by inversion. **Do not vortex.**
	Using fluorescence microscopy to view EmGFP titer	The signal level of EmGFP in the cells is not optimal for visual evaluation using fluorescence microscopy. We recommend using only flow cytometry to evaluate transduction efficiency.
No colonies obtained upon titering	Too much antibiotic used for selection	Determine the antibiotic sensitivity of your cell line by performing a kill curve experiment, and use the minimum concentration required to kill your untransduced cell line.
	Viral stocks stored incorrectly	Aliquot and store stocks at -80°C. Do not freeze/thaw more than 3 times.
	Polybrene® not included during transduction	Transduce the lentiviral construct into cells in the presence of Polybrene®.
Titer indeterminable; cells confluent	Too little antibiotic used for selection	Increase amount of antibiotic.
	Viral supernatant insufficiently diluted	Titer lentivirus using a wider range of 10-fold serial dilutions (*e.g.* 10^{-2} to 10^{-8}).

Transducing Mammalian Cells

The table below lists some potential problems and possible solutions that may help you troubleshoot your transduction and expression experiment.

Problem	Reason	Solution
No expression of the gene of interest	Promoter silencing	• Lentiviral constructs may integrate into a chromosomal region that silences the CMV promoter. Screen multiple antibiotic-resistant clones and select the one with the highest expression levels.
	Viral stocks stored incorrectly	Aliquot and store stocks at -80°C. Do not freeze/thaw more than 3 times.
	Frozen cells used for expression experiments for pLenti7.3 vector	pLenti7.3 vectors are designed for transient expression. We do **not** recommend using frozen cells for these expression experiments.

Continued on next page

Transducing Mammalian Cells, continued

Problem	Reason	Solution
Poor expression of the gene of interest	Low transduction efficiency: • Polybrene® not included during transduction • Non-dividing cell type used	• Transduce the lentiviral construct into cells in the presence of Polybrene®. • Transduce your lentiviral construct into cells using a higher MOI.
	MOI too low	Transduce your lentiviral construct into cells using a higher MOI.
	Too much antibiotic used for selection	Determine the antibiotic sensitivity of your cell line by performing a kill curve. Use the minimum antibiotic concentration required to kill your untransduced cell line.
	Cells harvested too soon after transduction	Do not harvest cells until at least 48-72 hours after transduction to allow expressed protein to accumulate in transduced cells.
	Gene of interest is toxic to cells	Generating constructs containing activated oncogenes or potentially harmful genes is not recommended.
Cytotoxic effects observed after transduction	Large volume of viral supernatant used for transduction	• Remove the "spent" media containing virus and replace with fresh, complete media. • Concentrate the virus (Yee, 1999).
	Polybrene® used during transduction	Verify the sensitivity of your cells to Polybrene®. If cells are sensitive, omit the Polybrene® during transduction.
	Too much antibiotic used for selection	Determine the antibiotic sensitivity of your cell line by performing a kill curve. Use the minimum concentration of antibiotic required to kill your untransduced cell line.
	Gene of interest is toxic to cells	Try a different cell line.

Appendix

Blasticidin

Description

Blasticidin S HCl is a nucleoside antibiotic isolated from *Streptomyces griseochromogenes* which inhibits protein synthesis in both prokaryotic and eukaryotic cells. Resistance is conferred by expression of either one of two Blasticidin S deaminase genes: *BSD* from *Aspergillus terreus* (Kimura *et al.*, 1994) or *bsr* from *Bacillus cereus* (Izumi *et al.*, 1991). These deaminases convert Blasticidin S to a non-toxic deaminohydroxy derivative (Izumi *et al.*, 1991).

Molecular Weight, Formula, and Structure

Merck Index: 12: 1350
MW: 458.9
Formula: $C_{17}H_{26}N_8O_5$-HCl



Handling Blasticidin

Always wear gloves, mask, goggles, and a laboratory coat when handling Blasticidin. Weigh out Blasticidin and prepare solutions in a hood.

Preparing and Storing Stock Solutions

- Blasticidin is soluble in water and acetic acid.
- Prepare a stock solution of 5 to 10 mg/ml Blasticidin in sterile water and filter-sterilize the solution.
- Aliquot in small volumes suitable for one time use and freeze at -20°C for long-term storage or store at +4°C for short term storage.
- Aqueous stock solutions are stable for 1 week at +4°C and 6-8 weeks at -20°C.
- pH of the aqueous solution should not exceed 7.0 to prevent inactivation of Blasticidin.
- Do not subject stock solutions to freeze/thaw cycles (**do not store in a frost-free freezer**).
- Upon thawing, use what you need and discard the unused portion.
- Medium containing Blasticidin may be stored at +4°C for up to 2 weeks.

Map and Features of pLP1

pLP1 Map

The figure below shows the features of the pLP1 vector. Note that the *gag* and *pol* genes are initially expressed as a gag/pol fusion protein, which is then self-cleaved by the viral protease into individual Gag and Pol polyproteins. The complete sequence of pLP1 is available for downloading from www.invitrogen.com or by contacting **Technical Support** (see page 40).



Comments for pLP1
8889 nucleotides

CMV promoter: bases 1-747
TATA box: bases 648-651
Human β-globin intron: bases 880-1320
HIV-1 gag/pol sequences: bases 1355-5661
gag coding sequence: bases 1355-2857
gag/pol frameshift: base 2650
pol coding sequence: bases 2650-5661
HIV-1 Rev response element (RRE): bases 5686-5919
Human β-globin polyadenylation signal: bases 6072-6837
pUC origin: bases 6995-7668 (C)
Ampicillin (*bla*) resistance gene: bases 7813-8673 (C)
bla promoter: bases 8674-8772 (C)

C=complementary strand

Continued on next page

Map and Features of pLP1, Continued

Features of pLP1

pLP1 (8889 bp) contains the following elements. Features have been functionally tested.

Feature	Benefit
Human cytomegalovirus (CMV) promoter	Permits high-level expression of the HIV-1 *gag* and *pol* genes in mammalian cells (Andersson *et al.*, 1989; Boshart *et al.*, 1985; Nelson *et al.*, 1987).
Human β-globin intron	Enhances expression of the *gag* and *pol* genes in mammalian cells.
HIV-1 *gag* coding sequence	Encodes the viral core proteins required for forming the structure of the lentivirus (Luciw, 1996).
HIV-1 *pol* coding sequence	Encodes the viral replication enzymes required for replication and integration of the lentivirus (Luciw, 1996).
HIV-1 Rev response element (RRE)	Permits Rev-dependent expression of the *gag* and *pol* genes
Human β-globin polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA.
pUC origin of replication (*ori*)	Permits high-copy replication and maintenance in *E. coli*.
Ampicillin (*bla*) resistance gene	Allows selection of the plasmid in *E. coli*.

Map and Features of pLP2

pLP2 Map

The figure below shows the features of the pLP2 vector. The complete sequence of pLP2 is available for downloading from www.invitrogen.com or by contacting **Technical Support** (see page 40).



Comments for pLP2
4180 nucleotides

RSV enhancer/promoter: bases 1-271
TATA box: bases 200-207
Transcription initiation site: base 229
RSV UTR: bases 230-271
HIV-1 Rev ORF: bases 391-741
HIV-1 LTR polyadenylation signal: bases 850-971
bla promoter: bases 1916-2014
Ampicillin (*bla*) resistance gene: bases 2015-2875
pUC origin: bases 3020-3693

Continued on next page

Map and Features of pLP2, Continued

Features of pLP2

pLP2 (4180 bp) contains the following elements. Features have been functionally tested.

Feature	Benefit
RSV enhancer/promoter	Permits high-level expression of the *rev* gene (Gorman *et al.*, 1982).
HIV-1 Rev ORF	Encodes the Rev protein that interacts with the RRE on pLP1 to induce Gag and Pol expression, and on the pLenti6/V5 expression vector to promote the nuclear export of the unspliced viral RNA for packaging into viral particles.
HIV-1 LTR polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA.
Ampicillin (*bla*) resistance gene	Allows selection of the plasmid in *E. coli*.
pUC origin of replication (*ori*)	Permits high-copy replication and maintenance in *E. coli*.

Map and Features of pLP/VSVG

pLP/VSVG Map

The figure below shows the features of the pLP/VSVG vector. The complete sequence of pLP/VSVG is available for downloading from www.invitrogen.com or by contacting **Technical Support** (see page 40).



Comments for pLP/VSVG
5821 nucleotides

CMV promoter: bases 1-747
TATA box: bases 648-651
Human β-globin intron: bases 880-1320
VSV G glycoprotein (VSV-G): bases 1346-2881
Human β-globin polyadenylation signal: bases 3004-3769
pUC origin: bases 3927-4600 (C)
Ampicillin (*bla*) resistance gene: bases 4745-5605 (C)
bla promoter: bases 5606-5704 (C)

C=complementary strand

Continued on next page

Map and Features of pLP/VSVG, Continued

Features of pLP/VSVG

pLP/VSVG (5821 bp) contains the following elements. Features have been functionally tested.

Feature	Benefit
Human CMV promoter	Permits high-level expression of the VSV-G gene in mammalian cells (Andersson *et al.*, 1989; Boshart *et al.*, 1985; Nelson *et al.*, 1987).
Human β-globin intron	Enhances expression of the VSV-G gene in mammalian cells.
VSV G glycoprotein (VSV-G)	Encodes the envelope G glycoprotein from Vesicular Stomatitis Virus to allow production of a pseudotyped retrovirus with a broad host range (Burns *et al.*, 1993; Emi *et al.*, 1991; Yee *et al.*, 1994).
Human β-globin polyadenylation signal	Allows efficient transcription termination and polyadenylation of mRNA.
pUC origin of replication (*ori*)	Permits high-copy replication and maintenance in *E. coli*.
Ampicillin (*bla*) resistance gene	Allows selection of the plasmid in *E. coli*.

Technical Support

Web Resources

Visit the Invitrogen web site at www.invitrogen.com for:

- Technical resources, including manuals, vector maps and sequences, application notes, MSDSs, FAQs, formulations, citations, handbooks, etc.
- Complete technical support contact information
- Access to the Invitrogen Online Catalog
- Additional product information and special offers

Contact Us

For more information or technical assistance, call, write, fax, or email. Additional international offices are listed on our web site (www.invitrogen.com).

Corporate Headquarters:
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail: tech_support@invitrogen.com

Japanese Headquarters:
Invitrogen Japan
LOOP-X Bldg. 6F
3-9-15, Kaigan
Minato-ku, Tokyo 108-0022
Tel: 81 3 5730 6509
Fax: 81 3 5730 6519
E-mail:
jpinfo@invitrogen.com

European Headquarters:
Invitrogen Ltd
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK
Tel: +44 (0) 141 814 6100
Tech Fax: +44 (0) 141 814 6117
E-mail: eurotech@invitrogen.com

MSDS

MSDSs (Material Safety Data Sheets) are available on our web site at www.invitrogen.com/msds.

Certificate of Analysis

Product qualification is described in the Certificate of Analysis (CofA), available on our website by product lot number at www.invitrogen.com/cofa.

Limited Warranty

Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, contact our Technical Support Representatives.

Invitrogen warrants that all of its products will perform according to specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Invitrogen Corporation's liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order.
Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore, Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Support Representatives.

Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.

Purchaser Notification

Introduction

Use of the ViraPower™ HiPerform™ Lentiviral Expression Kits is covered under the licenses detailed below.

Limited Use Label License No. 5: Invitrogen Technology

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Invitrogen Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. Email: outlicensing@invitrogen.com.

Continued on next page

Limited Use Label License No. 19: Gateway® Cloning Products

This product and its use is the subject of one or more of U.S. Patent Nos. 5,888,732, 6,143,557, 6,171,861, 6,270,969, and 6,277,608 and/or other pending U.S. and foreign patent applications owned by Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for profit entity). The purchase of this product does not convey a license under any method claims in the foregoing patents or patent applications, or to use this product with any recombination sites other than those purchased from Invitrogen Corporation or its authorized distributor. The right to use methods claimed in the foregoing patents or patent applications with this product for research purposes only can only be acquired by the use of Clonase™ purchased from Invitrogen Corporation or its authorized distributors. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the employment of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Notwithstanding the preceding, any buyer who is employed in an academic or government institution may transfer materials made with this product to a third party who has a license from Invitrogen under the patents identified above to distribute such materials. Transfer of such materials and/or information to collaborators does not convey rights to practice any methods claimed in the foregoing patents or patent applications. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that none of (i) this product, (ii) any of its components, or (iii) a method claim of the foregoing patents, was used in the manufacture of such product. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the use of this product to manufacture a protein for sale, provided that no method claim in the above patents was used in the manufacture of such protein. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to use this product for purposes other than those permitted above, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200.

Gateway® Clone Distribution Policy

For additional information about Invitrogen's policy for the use and distribution of Gateway® clones, see the section entitled **Gateway® Clone Distribution Policy**, page 47.

Continued on next page

Limited Use Label License No. 27: Lipofectamine™ 2000

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Use of this product in conjunction with methods for the introduction of RNA molecules into cells may require licenses to one or more patents or patent applications. Users of these products should determine if any licenses are required. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned by Invitrogen and claiming this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Limited Use Label License No. 28: CMV Promoter

The use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at 319-335-4546.

Continued on next page

Limited Use Label License No. 51: Blasticidin and the Blasticidin Selection Marker

Blasticidin and the blasticidin resistance gene (*bsd*) are the subject of U.S. Patent No. 5,527,701 sold under patent license for research purposes only. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Limited Use Label License No. 108: Lentiviral Technology

The Lentiviral Technology (based upon the lentikat™ system) is exclusively licensed from Cell Genesys, Inc., under U.S. Patent Nos. 5,686,279; 5,834,256; 5,858,740; 5,994,136; 6,013,516; 6,051,427; 6,165,782 and 6,218,187 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for non-human research use requires a license from Cell Genesys (Cell Genesys, Inc. 342 Lakeside Drive, Foster City, California 94404). The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer, including non-gene therapy research and target validation applications in laboratory animals (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Continued on next page

Limited Use Label License No. 109: Retroviral Helper Lines

Retroviral helper cell lines are licensed from Wisconsin Alumni Research Foundation., under U.S. Patent No. 5,124,263, and corresponding patents and applications in other countries for internal research purposes only. Use of these cell lines for Commercial Purposes requires a license from Invitrogen.

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Continued on next page

Limited Use Label License No. 308: WPRE Element in Lentiviral Vectors

This product contains the Woodchuck Post-transcriptional Regulatory Element ("WPRE") which is the subject of intellectual property owned by The Salk Institute for Biological Studies, and licensed to Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; and/or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. In addition, any use of WPRE outside of this product or the product's authorized use requires a separate license from the Salk Institute. Invitrogen will not assert a claim against the buyer of infringement of patents owned by Invitrogen and claiming this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product or for a Commercial Purpose. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008, Phone (760) 603-7200. Fax (760) 602-6500, or The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, Attn.: Office of Technology Management, Phone: (858) 453-4100 extension 1275, Fax: (858) 546-8093.

Information for European Customers

The 293FT cell line is genetically modified and carries the pUC-derived plasmid, pCMVSPORT6TAg.neo. As a condition of sale, this product must be in accordance with all applicable local legislation and guidelines including EC Directive 90/219/EEC on the contained use of genetically modified organisms.

Gateway® Clone Distribution Policy

Introduction

The information supplied in this section is intended to provide clarity concerning Invitrogen's policy for the use and distribution of cloned nucleic acid fragments, including open reading frames, created using Invitrogen's commercially available Gateway® Technology.

Gateway® Entry Clones

Invitrogen understands that Gateway® entry clones, containing *att*L1 and *att*L2 sites, may be generated by academic and government researchers for the purpose of scientific research. Invitrogen agrees that such clones may be distributed for scientific research by non-profit organizations and by for-profit organizations without royalty payment to Invitrogen.

Gateway® Expression Clones

Invitrogen also understands that Gateway® expression clones, containing *att*B1 and *att*B2 sites, may be generated by academic and government researchers for the purpose of scientific research. Invitrogen agrees that such clones may be distributed for scientific research by academic and government organizations without royalty payment to Invitrogen. Organizations other than academia and government may also distribute such Gateway® expression clones for a nominal fee ($10 per clone) payable to Invitrogen.

Additional Terms and Conditions

We would ask that such distributors of Gateway entry and expression clones indicate that such clones may be used only for research purposes, that such clones incorporate the Gateway® Technology, and that the purchase of Gateway® Clonase™ from Invitrogen is required for carrying out the Gateway® recombinational cloning reaction. This should allow researchers to readily identify Gateway® containing clones and facilitate their use of this powerful technology in their research. Use of Invitrogen's Gateway® Technology, including Gateway® clones, for purposes other than scientific research may require a license and questions concerning such commercial use should be directed to Invitrogen's licensing department at 760-603-7200.

References

Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (1989) Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. J. Biol. Chem. *264*, 8222-8229

Boshart, M., Weber, F., Jahn, G., Dorsch-Häsler, K., Fleckenstein, B., and Schaffner, W. (1985) A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus. Cell *41*, 521-530

Buchschacher, G. L., Jr., and Wong-Staal, F. (2000) Development of Lentiviral Vectors for Gene Therapy for Human Diseases. Blood *95*, 2499-2504

Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.-K. (1993) Vesicular Stomatitis Virus G Glycoprotein Pseudotyped Retroviral Vectors: Concentration to a Very High Titer and Efficient Gene Transfer into Mammalian and Nonmammalian Cells. Proc. Natl. Acad. Sci. USA *90*, 8033-8037

Ciccarone, V., Chu, Y., Schifferli, K., Pichet, J.-P., Hawley-Nelson, P., Evans, K., Roy, L., and Bennett, S. (1999) Lipofectamine™ 2000 Reagent for Rapid, Efficient Transfection of Eukaryotic Cells. Focus *21*, 54-55

Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., and Naldini, L. (1998) A Third-Generation Lentivirus Vector with a Conditional Packaging System. J. Virol. *72*, 8463-8471

Emi, N., Friedmann, T., and Yee, J.-K. (1991) Pseudotype Formation of Murine Leukemia Virus with the G Protein of Vesicular Stomatitis Virus. J. Virol. *65*, 1202-1207

Gorman, C. M., Merlino, G. T., Willingham, M. C., Pastan, I., and Howard, B. H. (1982) The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-mediated Transfection. Proc. Natl. Acad. Sci. USA *79*, 6777-6781

Izumi, M., Miyazawa, H., Kamakura, T., Yamaguchi, I., Endo, T., and Hanaoka, F. (1991) Blasticidin S-Resistance Gene (*bsr*): A Novel Selectable Marker for Mammalian Cells. Exp. Cell Res. *197*, 229-233

Kimura, M., Takatsuki, A., and Yamaguchi, I. (1994) Blasticidin S Deaminase Gene from *Aspergillus terreus* (*BSD*): A New Drug Resistance Gene for Transfection of Mammalian Cells. Biochim. Biophys. ACTA *1219*, 653-659

Lewis, P. F., and Emerman, M. (1994) Passage Through Mitosis is Required for Oncoretroviruses but not for the Human Immunodeficiency Virus. J. Virol. *68*, 510-516

Luciw, P. A. (1996) in *Fields Virology* (Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., and Straus, S. E., eds), 3rd Ed., pp. 1881-1975, Lippincott-Raven Publishers, Philadelphia, PA

Naldini, L. (1998) Lentiviruses as Gene Transfer Agents for Delivery to Non-dividing Cells. Curr. Opin. Biotechnol. *9*, 457-463

Naldini, L. (1999) in *The Development of Human Gene Therapy* (Friedmann, T., ed), pp. 47-60, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996) Efficient Transfer, Integration, and Sustained Long-Term Expression of the Transgene in Adult Rat Brains Injected with a Lentiviral Vector. Proc. Natl. Acad. Sci. USA *93*, 11382-11388

Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987) Negative and Positive Regulation by a Short Segment in the 5′-Flanking Region of the Human Cytomegalovirus Major Immediate-Early Gene. Molec. Cell. Biol. *7*, 4125-4129

Pandya, S., Klimatcheva, E., and Planelles, V. (2001) Lentivirus and foamy virus vectors: novel gene therapy tools Expert Opinion on Biological Therapy *1*, 17-40

Park, F., and Kay, MA. (2001) Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression *in vitro* and *in vivo*. Mol Ther. 4(3). 164-173

Sastry, L., Johnson, T., Hobson, M. J., Smucker, B., and Cornetta, K. (2002) Titering Lentiviral vectors:comparison of DNA, RNA and marker expression methods. Gene Ther. *9*, 1155-1162

Continued on next page

References, Continued

Takeuchi, S., Hirayama, K., Ueda, K., Sakai, H., and Yonehara, H. (1958) Blasticidin S, A New Antibiotic. The Journal of Antibiotics, Series A *11*, 1-5

White, S. M., Renda, M., Nam, N. Y., Klimatcheva, E., Y.Zhu, Fisk, J., Halterman, M., Rimel, B. J., Federoff, H., Pandya, S., Rosenblatt, J. D., and Planelles, V. (1999) Lentivirus vectors using human and simian imunodeficiency virus elements. J Virology *73*, 2832-2840

Yamaguchi, H., Yamamoto, C., and Tanaka, N. (1965) Inhibition of Protein Synthesis by Blasticidin S. I. Studies with Cell-free Systems from Bacterial and Mammalian Cells. J. Biochem (Tokyo) *57*, 667-677

Yee, J.-K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J. C., and Friedmann, T. (1994) A General Method for the Generation of High-Titer, Pantropic Retroviral Vectors: Highly Efficient Infection of Primary Hepatocytes. Proc. Natl. Acad. Sci. USA *91*, 9564-9568

Yee, J. K. (1999) in *The Development of Human Gene Therapy* (Friedmann, T., ed), pp. 21-45, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

Yee, J. K., Moores, J. C., Jolly, D. J., Wolff, J. A., Respess, J. G., and Friedmann, T. (1987) Gene Expression from Transcriptionally Disabled Retroviral Vectors. Proc. Natl. Acad. Sci. USA *84*, 5197-5201

Yu, S. F., Ruden, T. v., Kantoff, P. W., Garber, C., Seiberg, M., Ruther, U., Anderson, W. F., Wagner, E. F., and Gilboa, E. (1986) Self-Inactivating Retroviral Vectors Designed for Transfer of Whole Genes into Mammalian Cells. Proc. Natl. Acad. Sci. USA *83*, 3194-3198

Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, D. (1998) Self-inactivating lentivirus vector for safe and efficient *in vivo* gene delivery. J. Virol. 72. 9873-9880

invitrogen™

Corporate Headquarters
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008
T: 1 760 603 7200
F: 1 760 602 6500
E: tech.service@invitrogen.com

For country-specific contact information visit our web site at **www.invitrogen.com**